P-50 Hereditary angioedema breakthrough: FXII mutation discovery and the power of Icatibant and Lanadelumab Aviv Talmon, Limor Rubin, Yaarit Ribak, Oded Shamriz, Mariana Druker, Inon Sarig, Eyal Ben Dori, Yuval Tal Allergy and Clinical Immunology Unit, Department of Medicine, Hadassah Medical Organization, Faculty of Medicine, Hebrew University of Jerusalem, Israel Allergy, Asthma & Clinical Immunology 2025, 21(Suppl 2) :P-50 Background, Objectives: Hereditary angio-edema (HAE) is a rare, life-threatening disorder characterized by recurrent angioedema episodes
If fatigue suddenly worsens and coincides with any urinary symptoms, consider infection as the cause
If you receive a compounded semaglutide vial and it appears cloudy, discolored, or contains particles, do not use it
It must not be administered to humans or animals outside of approved clinical trials